Since the Department of Health and Human Services signed an interim enforcement discretion policy on October 28, 2026, published in the Federal Register on October 30, a simplified narrative has circulated among prescribers: that HHS has effectively cleared the path for peptide prescribing. This reading overstates what the policy does. The enforcement discretion applies to a narrow set of compounding activities under specific conditions, not to prescriber conduct. Prescribers who interpret the memo as personal protection against state medical board action, malpractice exposure, or scope-of-practice limits are reading more into the policy than it actually says.
What the HHS Enforcement Discretion Policy Actually Covers
The memo names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax, and TB-500. Each is limited to specific formulations and routes of administration. BPC-157 is covered for subcutaneous, intramuscular, oral, and topical use. Semax is covered for intranasal use. KPV is covered for oral and topical use. Injectable Semax and injectable KPV are not covered. No intravenous route is covered for any of the six peptides.
The policy directs enforcement discretion toward state-licensed pharmacies, federal facilities, and licensed physicians who compound these substances under specific conditions: bulk substances sourced from Section 510-registered establishments with certificates of analysis, CGMP compliance, single-ingredient products only, patient-specific prescriptions (no office stock), and reporting and labeling obligations. The conditions are substantial, and they fall almost entirely on the compounding side, not on prescribing.
What the Policy Does Not Cover
The memo is not FDA approval. The named peptides are not permanently on the Section 503A Bulks List, and the underlying statute has not changed. The policy addresses only federal enforcement intent and binds no state medical board, no state pharmacy board, and no state attorney general. Alabama, Mississippi, and South Carolina have issued prohibitions on peptide prescribing or compounding activities that the federal policy does not override.
The policy describes no immunity or safe harbor for prescribers. It does not shield a prescriber from state medical board inquiry. It does not create a standard of care for peptide prescribing. It does not alter the scope-of-practice rules in any state. It does not establish FDA endorsement that can be used in patient-facing marketing or advertising. HHS has retained the authority to revisit or withdraw the policy if safety or quality concerns arise, meaning the status today may not be the status six months from now.
What Prescribers Still Must Do
The memo does not change what prescribers already must do under their state medical practice act, their malpractice carrier’s expectations, and the generally recognized standard of care. Each peptide prescription still requires a documented medical necessity, informed consent that identifies the off-label or non-FDA-approved status of the product, a patient-specific prescription directed to a qualifying compounding pharmacy, and documentation that the prescribing physician has evaluated the patient within the applicable state examination requirements.
Prescribers should verify four separate items before writing a peptide prescription under the current federal policy: their state medical board’s position on peptide prescribing, their state pharmacy board’s position on peptide compounding, their malpractice carrier’s coverage of off-label and compounded therapy use, and any delegation framework under which they supervise mid-level providers performing peptide-related evaluations. Advertising and marketing claims that imply FDA endorsement remain outside what the policy authorizes.
Where to Get Current, Accredited Training
PracticalCME’s Peptides, IVs, and GLP-1s Certification Course is ACCME-accredited for 11.5 AMA PRA Category 1 Credits and covers the current regulatory framework for peptide prescribing, scope-of-practice variations across states, documentation and informed consent standards, and clinical evidence for the specific peptides named in the HHS policy. The course is revised as federal or state policy changes, which has been frequent through 2026. Each peptide covered in the course is addressed within the current enforcement framework rather than as a static reference, so prescribers who complete the course have the most recent guidance available at the time of study.

Gregory P. Zengo, MD, FACOG
Founder and Medical Director, PracticalCME
Board-certified physician and surgeon. Author of the PracticalCME Peptides, IVs, and GLP-1s Certification Course curriculum and the Botox and Dermal Filler curriculum first published in 2012. Twenty years of CME teaching. Instructor, Emory University Department of Gynecology and Obstetrics (1996 to 1998). MD, Emory University School of Medicine (1992); residency at Emory Gynecology and Obstetrics (1996). LinkedIn.
This article is continuing medical education and general professional information. It is not legal advice. Prescribers should consult their own counsel and their state medical board for guidance specific to their practice circumstances. Last reviewed: November 18, 2026.